CYP17A1型
前列腺癌
化学
药理学
哌啶
癌症研究
前列腺
活力测定
细胞色素P450
细胞培养
癌细胞
癌症
细胞生长
间质细胞
细胞
生物活性
雄激素受体
体内
生物化学
类固醇
信号转导
体外
CYP3A4型
药品
作者
Angelika Grudzińska,Jibira Yakubu,Chiara Vigato,Therina du Toit,Gaia Vanzetti,Radosław Zan,Donatella Boschi,Simonetta Oliaro‐Bosso,Fredrik Björkling,Flemming Steen Jørgensen,Amit V. Pandey,Tomasz M. Wróbel
出处
期刊:ChemMedChem
[Wiley]
日期:2026-10-04
卷期号:21 (19): e70336-e70336
被引量:1
摘要
Castration‐resistant prostate cancer relies on intratumoral androgen synthesis mediated by cytochrome P450 17A1 (CYP17A1). Treatment with the only clinically used CYP17A1 inhibitor, abiraterone, is limited by resistance and side effects, underscoring the urgent need for new CYP17A1 inhibitors with greater selectivity and improved safety profiles. In response to this challenge, we designed, synthesized, and biologically evaluated 30 novel piperidine derivatives. All compounds were initially screened in the H295R cell line to assess their inhibitory activity toward both CYP17A1 and off‐target CYP21A2. Compounds were further evaluated in cell viability assays using prostate cancer cells and a normal prostate cell line. The most potent and selective compounds were subjected to further biological studies: IC 50 determination, steroid profiling, cell migration assay, aldo–keto reductase family 1 member C3 inhibition assays, absorption, distribution, metabolism, and excretion prediction, and solubility testing. Several compounds emerged as the most active and selective leads, highlighting their potential for pharmaceutical development.
科研通智能强力驱动
Strongly Powered by AbleSci AI